$2.93
-0.05-1.68%
At close: -
$2.98
0.051.71%
After Hours: Apr 16, 4:00 PM EDT
Comments
Loading...
Adverum Biotechnologies Analyst Ratings and Price Targets | NASDAQ:ADVM | Benzinga
Adverum Biotechnologies Inc has a consensus price target of $22.43 based on the ratings of 7 analysts. The high is $40 issued by Truist Securities on August 14, 2024. The low is $2 issued by Ladenburg Thalmann on March 7, 2023. The 3 most-recent analyst ratings were released by Chardan Capital, RBC Capital, and HC Wainwright & Co. on April 17, 2025, April 16, 2025, and April 16, 2025, respectively. With an average price target of $22.67 between Chardan Capital, RBC Capital, and HC Wainwright & Co., there's an implied 660.63% upside for Adverum Biotechnologies Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
RBC Capital
HC Wainwright & Co.
Truist Securities
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Adverum Biotechnologies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | 1007.38% | Chardan Capital | Daniil Gataulin39% | $40 → $33 | Maintains | Buy | Get Alert |
| 04/16/2025 | Buy Now | 67.79% | RBC Capital | Luca Issi37% | $10 → $5 | Maintains | Sector Perform | Get Alert |
| 04/16/2025 | Buy Now | 906.71% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 906.71% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | 235.57% | RBC Capital | Luca Issi37% | $12 → $10 | Maintains | Sector Perform | Get Alert |
| 08/14/2024 | Buy Now | 1242.28% | Truist Securities | Joon Lee76% | $60 → $40 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 906.71% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 302.68% | RBC Capital | Luca Issi37% | $15 → $12 | Maintains | Sector Perform | Get Alert |
| 07/18/2024 | Buy Now | 1242.28% | Chardan Capital | Daniil Gataulin39% | $4 → $40 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 738.93% | Oppenheimer | Francois Brisebois40% | → $25 | Initiates | → Outperform | Get Alert |
| 05/15/2024 | Buy Now | 1913.42% | Truist Securities | Joon Lee76% | $60 → $60 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 906.71% | HC Wainwright & Co. | Matthew Caufield36% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 906.71% | HC Wainwright & Co. | Matthew Caufield36% | → $30 | Initiates | → Buy | Get Alert |
| 04/29/2024 | Buy Now | 638.26% | Mizuho | Graig Suvannavejh50% | $40 → $22 | Maintains | Buy | Get Alert |
| 03/19/2024 | Buy Now | 34.23% | Chardan Capital | Daniil Gataulin39% | $4 → $40 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | -32.89% | RBC Capital | Luca Issi37% | $30 → $20 | Maintains | Sector Perform | Get Alert |
| 02/06/2024 | Buy Now | 34.23% | Mizuho | Graig Suvannavejh50% | $20 → $40 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | -32.89% | Mizuho | Graig Suvannavejh50% | → $20 | Initiates | → Buy | Get Alert |
| 09/05/2023 | Buy Now | 101.34% | Truist Securities | Joon Lee76% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 34.23% | Chardan Capital | Daniil Gataulin39% | $20 → $40 | Upgrade | Neutral → Buy | Get Alert |
| 03/07/2023 | Buy Now | -32.89% | Ladenburg Thalmann | Aydin Huseynov33% | → $20 | Initiates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | -32.89% | Chardan Capital | Daniil Gataulin39% | $25 → $20 | Maintains | Neutral | Get Alert |
| 11/11/2022 | Buy Now | 0.67% | RBC Capital | Luca Issi37% | $50 → $30 | Maintains | Sector Perform | Get Alert |
| 08/12/2022 | Buy Now | -16.11% | Chardan Capital | Daniil Gataulin39% | $30 → $25 | Maintains | Neutral | Get Alert |
| 07/07/2022 | Buy Now | 34.23% | Truist Securities | Joon Lee76% | $30 → $40 | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Adverum Biotechnologies (ADVM) stock?
The latest price target for Adverum Biotechnologies (NASDAQ:ADVM) was reported by Chardan Capital on April 17, 2025. The analyst firm set a price target for $33.00 expecting ADVM to rise to within 12 months (a possible 1007.38% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?
The latest analyst rating for Adverum Biotechnologies (NASDAQ:ADVM) was provided by Chardan Capital, and Adverum Biotechnologies maintained their buy rating.
When was the last upgrade for Adverum Biotechnologies (ADVM)?
The last upgrade for Adverum Biotechnologies Inc happened on August 11, 2023 when Chardan Capital raised their price target to $4. Chardan Capital previously had a neutral for Adverum Biotechnologies Inc.
When was the last downgrade for Adverum Biotechnologies (ADVM)?
There is no last downgrade for Adverum Biotechnologies.
When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a maintained with a price target of $40.00 to $33.00. The current price Adverum Biotechnologies (ADVM) is trading at is $2.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
